Amol Akhade/LinkedIn
Jun 13, 2024, 03:19
Amol Akhade: Everolimus vs Alpelisib vs Capivasertib
Amol Akhade, Consultant Medical Oncologist atSuyog Cancer Clinics, shared a post on X:
“Everolimus vs Alpelisib vs Capivasertib.
Even though PFS HR are similar for all 3 drugs, only capivasertib has phase III data in patients with cdk4- 6 exposure.
Toxicity profile for capivasertib is better as compared to alpelisib, especially for rash and hyperglycaemia.”
Source: Amol Akhade/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 3, 2024, 05:43
Dec 3, 2024, 05:40
Dec 3, 2024, 05:36
Dec 3, 2024, 05:11
Dec 3, 2024, 05:06
Dec 3, 2024, 05:01
Dec 3, 2024, 04:55
Dec 3, 2024, 04:51
Dec 3, 2024, 03:59
Dec 3, 2024, 03:53
Dec 3, 2024, 03:41